R ecent discoveries suggest that adipose tissue can synthesise and secrete mediators that contribute to the pathogenesis of type 2 diabetes mellitus and cardiovascular disease, leading to the concept of 'adipose tissue as an endocrine organ'. These mediators include tumour necrosis factor-α, interleukin-6, adiponectin, resistin, plasminogen activator inhibitor type 1 and angiotensin II. They modify the activity of regulatory enzymes in adipocyte metabolism, alter the release of non-esterified fatty acids and affect glucose uptake. They may also have direct actions on the vascular endothelium. The diverse effects of these mediators support the notion that inflammation plays a role in metabolic and vascular disease, at least in part via adipocyte-derived cytokines.
Introduction
The primary function of adipose tissue is to store and release energy. Adipocytes are specifically adapted for this purpose; they can undertake massive expansion in volume, increasing their capacity to store excess fuel substrate in the form of triglyceride (TG). The process of fuel deposition and mobilisation is regulated by the interaction of several hormones which modify the activity of regulatory enzymes (figure 1). In essence, fasting favours lipolysis, which is the hydrolysis of TG to non-esterified fatty acids (NEFA) and glycerol; conversely, in the postprandial state, the balance shifts to promote lipogenesis, namely the uptake and storage of NEFA as TG in adipocytes. One of the key regulators of this process is insulin. Increased circulating insulin after a meal increases lipoprotein lipase (LPL) activity which hydrolyses circulating lipoproteins to release NEFA; these NEFA are then taken up into the adipocyte to form triglyceride. Insulin also inhibits the activity of hormone sensitive lipase (HSL) in adipocytes, thereby preventing lipolysis of stored TG. Type 2 diabetes and obesity are characterised by cellular insulin resistance. 1 Over 30 years ago Randle 2 hypothesised that NEFA may contribute to the development of insulin resistance in skeletal muscle. Although this hypothesis has since been revised, the central tenet holds true. NEFA impair the insulin-signalling cascade; insulin-stimulated phosphatidylinositol 3-kinase (PI 3-kinase) activity is reduced by lipid infusion, in part by activation of certain isoforms of protein kinase C and phosphorylation of serine residues on the insulin receptor substrate (IRS) proteins. 3 During hyperglycaemia there is reduced oxidation of NEFA in skeletal muscle, favouring local triglyceride deposition 4 (see below). The release of NEFA by adipose tissue may not only have an effect on insulin action in muscle and fat: endothelium-dependent vasodilation is reduced after circulating NEFA levels are raised by infusion of intralipid and heparin. 5 
Visceral adiposity and non-adipose triglyceride deposition
Prospective studies have demonstrated a relationship between visceral adiposity and the development of type 2 diabetes. 6 This pattern of adiposity reflects the deposition of fat in the omentum 
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and around viscera -and in particular, there is a strong association between fat deposition in the liver (hepatic steatosis) and insulin resistance. One explanation for the role of visceral adiposity in insulin resistance may be that this fat is less insulin sensitive than subcutaneous adipose tissue, while the venous effluent from abdominal adipose depots may deliver high concentrations of NEFA to the liver, increasing hepatic glucose output 7 and triglyceride synthesis in the form of very low-density lipoprotein (VLDL). However, triglyceride is also deposited in skeletal muscle, the extent of which again correlates with both visceral adiposity (reviewed by Kelley and Goodpaster 8 ) and insulin resistance. Subjects with high intramyocellular lipid in skeletal muscle also have high levels of circulating NEFA in association with reduced insulin-stimulated activation of PI 3-kinase. 9 That adipose tissue may have an important role in determining skeletal muscle and, perhaps, hepatic insulin sensitivity, was highlighted in mice with specific adipose tissue resistance to insulin-stimulated glucose uptake (via tissue-specific knockout of GLUT4). In these animals, insulin sensitivity was also reduced in liver and skeletal muscle in vivo, 10 although normal insulin sensitivity returned when these tissues were studied in isolation in vitro. Thus, there appears to be one or more signals from adipose tissue that influence insulin sensitivity in skeletal muscle. Intriguingly, in these animals, circulating NEFA were not elevated, suggesting that there may be hormonal adipocyte-derived factors, essentially defining adipose tissue as an endocrine organ. Adipose tissue in fact secretes several factors that appear to have endocrine, paracrine or autocrine effects (table 1) . 11 Moreover, their effects are not only on insulin action: vascular function, haemostasis and inflammation may also be affected. Here we review the mediators secreted by adipocytes which appear to influence the development of cardiovascular disease, focusing on those more recently discovered.
Adipocytes, cytokines and metabolism
Several adipocyte-secreted factors have been identified that have regulatory roles in metabolism, and in particular in modifying insulin sensitivity (table 1) . Those with the most relevance to diabetes and vascular disease are reviewed below.
Leptin
The main role of the peptide hormone leptin is to regulate energy metabolism, predominantly by signalling to the hypothalamus and causing a reduction in food intake and subsequent weight loss (reviewed by Caro et al.) . 12 Obesity is characterised by hyperleptinaemia. Leptin deficiency 13 and defects in the leptin receptor, 14 while described in humans, appear rare. Leptin is secreted by adipocytes in response to various signals, with insulin stimulating and catecholamines suppressing its release. Other hormones, such as glucocorticoids and thyroxine, may also influence leptin secretion, while prolonged exposure to the cytokines TNF-α (see below) and TGF-β1 reduce adipocyte leptin secretion. Leptin release is influenced by nutritional status; on fasting, circulating leptin falls, while on overeating, levels rise. Release is greater from larger adipocytes, and from subcutaneous as opposed to visceral adipose depots. 15 Leptin has been shown to improve some actions of insulin in rodents, via additional mechanisms to weight loss through anorexia. Leptin may have a direct effect on insulin-sensitive tissues to increase lipid oxidation and suppress lipid synthesis in skeletal muscle. 16 
Resistin
From the observation that the thiazolidinedione (TZD) class of drugs improve insulin sensitivity in adipose tissue, Steppan and colleagues 17 hypothesised the existence of an adipose tissue factor that modifies insulin sensitivity. By screening the adipocyte genes that are regulated by TZDs in mice, they identified a novel cysteine-rich polypeptide, expression of which is reduced in adipose tissue exposed to TZDs. Levels of this peptide, which they named 'resistin', increase in response to high-fat feeding, while administration of anti-resistin IgG to these animals prevents the insulin resistance and hyperglycaemia associated with high dietary fat intake. Furthermore, the incubation of 3T3-L1 adipocytes with resistin reduces insulin-stimulated glucose uptake. Thus, resistin appears to be an adipocyte-derived factor that induces insulin resistance, certainly in adipose tissue. Effects in other tissues, and its role in human physiology, remain to be characterised.
Adiponectin
While TZDs reduce the adipocyte secretion of resistin, they also increase secretion of an alternative blood-borne factoradiponectin. Plasma levels of adiponectin are reduced in obese humans. 18 In mice fed a high-fat diet, 19 plasma levels fall in association with hyperinsulinaemia and hyperglycaemia. This, however, is reversed by concurrent treatment with a TZD. In addition, VOLUME in animals lacking adipose tissue and, therefore, adiponectin, a syndrome of insulin resistance is observed, characterised also by increases in circulating NEFA and TG deposition in skeletal muscle. This insulin resistance is largely reversed by administration of adiponectin, though interestingly a more complete reversal is observed in response to leptin co-administered with adiponectin. It appears that adiponectin acts on skeletal muscle to increase NEFA oxidation and reduce triglyceride content, and there may be an additional effect to also reduce hepatic TG deposition. Adiponectin is thus a candidate as a future pharmacological insulin-sensitising agent.
Tumour necrosis factor-alpha
Tumour necrosis factor-alpha (TNF-α) is an inflammatory cytokine, produced mainly by macrophages, and also secreted by adipose tissue. 20 Early observations demonstrated that TNF-α levels are elevated in animal models of obesity and insulin resistance, while neutralisation of TNF-α in these animals increases insulin sensitivity. Moreover, expression of adipose tissue TNF-α mRNA is elevated in obesity. Adipose tissue TNF-α production correlates positively with serum insulin and body mass index (BMI), while weight loss results in a fall in TNF-α expression. 1 Interestingly, despite the increased levels of TNF-α expression in obese subjects, only very low levels of circulating TNF-α are detected in peripheral blood, suggesting that its role may be mainly autocrine or paracrine in this setting.
TNF-α has several effects on adipose tissue. It reduces activity of lipoprotein lipase and increases hormone-sensitive lipase activity, thus increasing NEFA release. In addition it decreases expression of the insulin-responsive glucose transporter GLUT4, reduces insulin-stimulated activation of the insulin receptor and IRS proteins and downregulates peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression (reviewed by Hube et al.) . 21 Similar effects are also seen in the vasculature; aortic endothelial cells pretreated with TNF-α display reduced insulin-stimulated activation of PI 3-kinase and production of nitric oxide -a further potential link between metabolic and vascular disease.
Transforming growth factor-beta
Transforming growth factor-beta (TGF-β) is a further cytokine secreted by adipose tissue. Adipose tissue TGF-β1 expression is correlated with BMI, 22 while it appears that TGF-β1 stimulates the release of plasminogen activator inhibitor type 1 (PAI-1) 23 via locally expressed TGF-β1 type 2 and 3 receptors. In contrast to TNF-α, TGF-β1 suppresses release of leptin from human adipose tissue. However, it shares more general effects on adipocyte behaviour with TNF-α, reducing the expression of genes involved in the differentiation of preadipocytes into adipocytes. 24 
Interleukins
Both interleukin-6 (IL-6), and more recently interleukin-8 (IL-8), 25 have been identified as cytokines that are secreted by adipose tissue. They may have several roles in regulating adipocyte metabolism; IL-6 reduces the activity of LPL, thus reducing the availability of intracellular substrate for triglyceride synthesis, and may have a role in the regulation of thermogenesis and oestrogen metabolism. In addition, IL-8 has a direct effect on endothelial cells to attract monocytes and promote vascular smooth muscle cell migration, 26 reinforcing the potential direct link between adiposity, cytokine secretion and vascular disease.
IL-6 secretion from adipose tissue depots is related to waist:hip ratio and BMI, 27 while release is greater from visceral than subcutaneous depots. In a study of the effects of weight loss on whole body and adipose tissue cytokine production, 28 relationships were demonstrated between serum IL-6, TNF-α, leptin and BMI. After multivariate analysis, IL-6 independently correlated with BMI and the fasting insulin resistance index, reinforcing its link with the insulin resistance syndrome. Up to 25% of circulating IL-6 may be derived from adipose tissue, 27 although only 10% is from adipocytes, suggesting that other cells, such as stromal cells, play a significant role. The regulation of adipose tissue IL-6 and IL-8 secretion may be largely controlled by TNF-α; large increases in IL-6 secretion from 3T3-L1 adipocytes are observed in response to TNF-α stimulation. 29 From the above studies, it becomes apparent that the effect of stimulation of adipose tissue by TNF-α and IL-6 is to increase lipolysis and NEFA release, while resistin and adiponectin may affect glucose uptake. In addition, the systemic release of NEFA, and potentially IL-6, provides a means of indirectly reducing insulin sensitivity in other organs.
Adipocyte-derived factors and the vasculature
In addition to those factors that may influence metabolism and tissue inflammation, adipose tissue also produces PAI-1 and angiotensin II (Ang II), both of which may have direct effects to promote thrombosis and vascular injury.
Plasminogen activator inhibitor type 1
Plasminogen activator inhibitor type 1 (PAI-1), a serine protease inhibitor that inhibits fibrinolysis, is released by human adipose tissue. 30 Elevated circulating levels are associated with the presence of vascular disease, while relationships are also observed with obesity and other features of the insulin resistance syndrome. 31 The amount of PAI-1 secreted from adipose tissue correlates with plasma PAI-1, suggesting a significant contribution from adipose tissue, 32 and is more marked from visceral than subcutaneous adipose tissue. The adipose tissue production of PAI-1 is increased by TNF-α, TGF-β, IL-1β 33 and Ang II, and may be modified by insulin, oestrogen and glucocorticoids. Similar to the interleukins, TNF-α appears to have a major role in determining adipose tissue and circulating PAI-1 levels; TNF-α increases the expression of PAI-1 in murine adipose tissue, while its neutralisation is accompanied by a fall in both plasma PAI-1 levels and adipose tissue PAI-1 expression. 34 
Angiotensin II
Expression of angiotensinogen (AGT), angiotensin-converting enzyme and the angiotensin II type 1 (AT 1 ) receptor genes has been confirmed in human adipose tissue (reviewed by Engeli et al.) . 35 To confirm the presence of a true local RAS it is necessary to confirm REVIEW the presence of the renin gene but, to date, only one group has identified renin mRNA in human adipose tissue. 36 The RAS has a potentially important role in the regulation of body weight and fat mass. This may be partly mediated by a central anorectic effect via the AT 1 -receptor, and partly by effects in adipose tissue, possibly by local potentiation of the sympathetic nervous system. The adipose tissue RAS seems to be influenced by nutritional status, with local expression of AGT mRNA falling during fasting, while epididymal fat from animal models of obesity secretes twice as much AGT as lean controls. 37 Other factors may influence the expression of the components of the RAS in adipose tissue: both glucocorticoids and fatty acids increase AGT synthesis.
Ang II appears to play an important role in stimulating the differentiation of pre-adipocytes into adipocytes -an effect that is most likely paracrine in nature. Adipose tissue release of Ang II may also affect the vasculature by stimulating adipocytes to release the potent vasodilator prostaglandin I 2 which is derived from arachidonic acid. 38 It seems less likely that adipose tissue production of Ang II has important direct vascular effects in the systemic circulation. However, a recent publication demonstrated that Ang II stimulates adipocyte PAI-1 release via the AT 1 -receptor. As blockade of this receptor in the absence of exogenous Ang II still reduces PAI-1 release, it is possible that this effect is mediated by adipocyte-derived Ang II.
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Inflammatory markers, insulin resistance and vascular disease
The systemic importance of inflammatory cytokines produced by adipose tissue remains unclear. Since both insulin resistance and disease of the vasculature appear to have an inflammatory component, it is attractive to hypothesise that adipose tissue may play an active role in obesity-associated type 2 diabetes and atherosclerosis. In a cross-sectional study, Yudkin and colleagues 40 found associations between C-reactive protein (CRP), IL-6, TNF-α and obesity. In addition, CRP was related to insulin resistance, raised blood pressure and endothelial dysfunction. These findings were interpreted as supporting an aetiological link between low-grade inflammation and components of the metabolic syndrome, in particular insulin resistance and endothelial dysfunction. Prospective studies also suggest that inflammation may play a role in the development of diabetes; elevated IL-6 levels have been reported to predict future diabetes in an otherwise healthy population. 41 It is intriguing to consider that pharmacological agents which might reduce the development of diabetes (pravastatin, 42 ramipril 43 ) could possibly do so by their anti-inflammatory actions. In keeping with this, and offering a potential mechanism for inflammation-associated insulin resistance, treatment with high-dose salicylic acid was shown recently to reduce the skeletal muscle insulin resistance associated with lipid infusion. The mechanism appeared to involve a reduction in serine phosphorylation of insulin receptor substrate-1 (IRS-1) via suppression of the serine kinase IκB kinase-β (IKK-β). 44 
Conclusions
With the Westernisation of dietary patterns and the increasing worldwide prevalence of obesity, type 2 diabetes and consequent vascular disease, understanding the nature and risks of excess adipose tissue assumes considerable scientific and clinical importance. There is now good evidence that human adipose tissue secretes several cytokines that have a paracrine, and possibly endocrine, influence on metabolic function and inflammatory activation. The emerging concept that low-grade chronic 
